A CALL TO ACTION: INCREASE FEDERAL FUNDING TO $60M IN FY23 FOR LUNG CANCER RESEARCH!

The Lung Cancer Research Program (LCRP) was established in fiscal year 2009 (FY09) with a congressional appropriation of $20 million, within the Congressionally Directed Medical Research Programs administered by the Department of Defense to support high-impact, innovative lung cancer research.

LCRP VISION: To eradicate deaths and suffering from lung cancer to better the health and welfare of the Service Members, Veterans, and the American public.

LCRP MISSION: Support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, and treatment for the control and cure of lung cancer.

FUNDING HISTORY
Over its 13-year history, the LCRP funding has had some fluctuation from year to year, affecting its ability to fund only 70% of research proposals rated excellent or outstanding by reviewers. This bar graph shows the program’s funding from 2009 to 2021, totaling $175.5M since its inception.

RESEARCH PORTFOLIO
The pie chart displays the LCRP portfolio from FY09-FY20, based on the program’s areas of emphasis, investment in terms of dollars and percentage of funding; and number of awards made for each.

Total Investment: $134.95M; Total Awards: 309

Congress must answer the call to action for lung cancer, the leading cause of cancer deaths in the U.S. Increase federal funding to $60M in FY23!